Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Alflorex® Bei Reizdarm, a Probiotic Containing Bifidobacterium Longum 35624®, in Patients With Irritable Bowel Syndrome in Medical Practice

NCT04859075 is registered in ClinicalTrials.gov with Medice Arzneimittel Pütter GmbH & Co KG as lead sponsor.

NCT NCT04859075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04859075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Alflorex® Bei Reizdarm, a Probiotic Containing Bifidobacterium Longum 35624®, in Patients With Irritable Bowel Syndrome in Medical Practice
Lead sponsor
Medice Arzneimittel Pütter GmbH & Co KG
Phase
Observational
Overall status
Terminated
Start date
May 5, 2021
Completion date
November 9, 2021
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome